Featured Research

from universities, journals, and other organizations

Reference pricing for proton therapy will help establish clinical benefits

Date:
April 21, 2014
Source:
Perelman School of Medicine at the University of Pennsylvania
Summary:
"Reference pricing” for proton therapy has been proposed by researchers. This is a relatively new model that establishes a standard price for different therapies with similar outcomes. Proton therapy is in the proverbial chicken or the egg scenario. Companies are pulling back on reimbursements to treat some cancers—notably prostate, breast and lung—because of the added expense and limited evidence to back it up. But in order to demonstrate the technology’s clinical benefit—which is showing promise as a more effective and better tolerated radiation—more studies with patients are needed.

Proton therapy is in the proverbial chicken or the egg scenario. Companies are pulling back on reimbursements to treat some cancers -- notably prostate, breast and lung -- because of the added expense and limited evidence to back it up. But in order to demonstrate the technology's clinical benefit -- which is showing promise as a more effective and better tolerated radiation -- more studies with patients are needed. So which should come first?

Both, say Abramson Cancer Center physicians Justin E. Bekelman, MD, an assistant professor of Radiation Oncology at the Perelman School of Medicine at the University of Pennsylvania, and Stephen M. Hahn, MD, chair of Radiation Oncology. In an article published today in the Journal of Clinical Oncology, the authors propose "reference pricing" -- a relatively new model that establishes a standard price for different therapies with similar outcomes. It would expand the patient base because of increased, cheaper coverage and thus research to establish whether its novel advantages translate into clinical benefits.

In this case, proton therapy should be set at the less expensive rate currently paid for intensity-modulated radiation therapy (IMRT), which is covered under most insurance plans, and Medicare and Medicaid, the authors propose.

Having found success with this model with private insurers since it was implemented in 2010, the University of Pennsylvania Health System is leading the way for other centers -- which are popping up around the country -- to make other treatments options more accessible to patients while moving the field along even further.

"We want to be a responsible leader for both patients and payers," said Bekelman. "This proposal does just that. This is an important and promising therapy for patients. We need to generate evidence to see whether proton therapy is better or equivalent to other modalities."

Next month, the Health Technology Assessment Program (HTAP) in Washington state will decide whether and under what circumstances the state's public payers will pay for proton therapy -- a decision that could have powerful influence over payment policies of other payers in the U.S. health care system. The HTAP has a unique legislative mandate in the U.S. to evaluate health technologies and translate evidence of comparative and cost effectiveness into payment policy.

This examination of proton therapy comes at decisive moment, as major insurers have recently announced policies that restrict coverage for proton therapy for certain cancers.

"HTAP should not follow suit," said Bekelman. "We propose a better way forward with reference pricing. By linking payment for proton therapy to evidence development, we echo prior calls to tie reimbursement for unproven technologies to the broad mandate of comparative effectiveness research with randomized trials."

When compared to conventional radiation therapies, proton therapy stands to offer several benefits for patients who are candidates, including decreased radiation to normal tissues, decreased side effects and complications, and the ability to re-treat tumors after recurrences. Every day, over 100 patients are treated at Penn Medicine's Roberts Proton Therapy Center. Several studies have shown such advantages, but what's lacking is randomized clinical trials.

Moving forward, the authors call for the HTAP to lead the way by deciding on behalf of its public payers to cover proton therapy under a policy of reference pricing with evidence development. They also call for a national proton therapy clinical trials consortium, led by physicians, and comprised of patients, payers, federal agencies, and device manufacturers, to jump start, design and fund research-related costs for high-quality multi-center comparative effectiveness studies.

"The tradeoff is justifiable," the authors write. "We will have reduced reimbursement, at least for a time, to promote evidence generation for a technology that or may not lead to better outcomes for great number of patients."

"This will preserve access to the technology and renew efforts to conduct crucial research," they add.


Story Source:

The above story is based on materials provided by Perelman School of Medicine at the University of Pennsylvania. Note: Materials may be edited for content and length.


Journal Reference:

  1. J. E. Bekelman, S. M. Hahn. Reference Pricing With Evidence Development: A Way Forward for Proton Therapy. Journal of Clinical Oncology, 2014; DOI: 10.1200/JCO.2014.55.6613

Cite This Page:

Perelman School of Medicine at the University of Pennsylvania. "Reference pricing for proton therapy will help establish clinical benefits." ScienceDaily. ScienceDaily, 21 April 2014. <www.sciencedaily.com/releases/2014/04/140421164144.htm>.
Perelman School of Medicine at the University of Pennsylvania. (2014, April 21). Reference pricing for proton therapy will help establish clinical benefits. ScienceDaily. Retrieved September 16, 2014 from www.sciencedaily.com/releases/2014/04/140421164144.htm
Perelman School of Medicine at the University of Pennsylvania. "Reference pricing for proton therapy will help establish clinical benefits." ScienceDaily. www.sciencedaily.com/releases/2014/04/140421164144.htm (accessed September 16, 2014).

Share This



More Health & Medicine News

Tuesday, September 16, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

President To Send 3,000 Military Personnel To Fight Ebola

President To Send 3,000 Military Personnel To Fight Ebola

Newsy (Sep. 16, 2014) President Obama is expected to send 3,000 troops to West Africa as part of the effort to contain Ebola's spread. Video provided by Newsy
Powered by NewsLook.com
Man Floats for 31 Hours in Gulf Waters

Man Floats for 31 Hours in Gulf Waters

AP (Sep. 16, 2014) A Texas man is lucky to be alive after he and three others floated for more than a day in the Gulf of Mexico when their boat sank during a fishing trip. (Sept. 16) Video provided by AP
Powered by NewsLook.com
Ivorians Abandon Monkey Pets in Fear Over Ebola Virus

Ivorians Abandon Monkey Pets in Fear Over Ebola Virus

AFP (Sep. 16, 2014) Since the arrival of Ebola in Ivory Coast, Ivorians have been abandoning their pets, particularly monkeys, in the fear that they may transmit the virus. Duration: 00:47 Video provided by AFP
Powered by NewsLook.com
Study Links Male-Pattern Baldness To Prostate Cancer

Study Links Male-Pattern Baldness To Prostate Cancer

Newsy (Sep. 16, 2014) New findings suggest men with a certain type of baldness at age 45 are 39 percent more likely to develop aggressive prostate cancer. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

      Technology News



      Save/Print:
      Share:

      Free Subscriptions


      Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

      Get Social & Mobile


      Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

      Have Feedback?


      Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
      Mobile: iPhone Android Web
      Follow: Facebook Twitter Google+
      Subscribe: RSS Feeds Email Newsletters
      Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins